Bone and Cancer
Bone and Cancer
Bone and CancerBone and Cancer Foundation, PO Box 287452 Bone and Cancer New York, NY 10128-0025  
Toll Free: 888 862-0999 Bone and Cancer Email: bcfdn@aol.com  
Bone and Cancer

Clinical Trials

Accolate

The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Company:

Approval Status:

Approved October 1996

Specific Treatments:

asthma

General Information

Accolate (zafirlukast) has been approved for the preventative and chronic treatment of asthma in adults and children 12 years of age and older.

Clinical Results

Accolate has been studied in more than 4,000 people worldwide. In clinical trials in patients with mild to moderate asthma, Accolate was shown to improve lung function and reduce daytime and nighttime asthma symptoms.

Mechanism of Action

Accolate is the first leukotrine receptor antagonist, a new class of drugs, to receive FDA clearance. Accolate works by blocking the effect of leukotrines, natural substances in the body that can contribute to asthma symptoms.

Additional Information

More than 12 million Americans suffer from asthma, and worldwide more than 100 million people have this chronic lung disease.

 How To Order Publications:
  Glossary
  FAQ

Information About

Clinical Trials



 

 

 

 

 

 

 

 

 

 

 


 

 

 

 

 

 

 


  Copyright 2011 - The Bone and Cancer Foundation